Ticker

Analyst Price Targets — STVN

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
March 5, 2026 2:12 pmPaul KnightKeyBanc$32.00$16.01StreetInsider Stevanato Group S.p.A. (STVN) PT Lowered to $32 at KeyBanc
February 10, 2026 2:10 pmJefferies$17.50$15.95TheFly Stevanato Group price target lowered to $17.50 from $23 at Jefferies
December 1, 2025 9:33 pmMorgan Stanley$24.00$22.58TheFly Stevanato Group assumed with an Equal Weight at Morgan Stanley
August 7, 2024 6:36 amPatrick DonnellyCitigroup$28.00$19.87TheFly Stevanato Group price target lowered to $28 from $30 at Citi
July 15, 2024 8:00 amDrew RanieriMorgan Stanley$22.00$21.71TheFly Stevanato Group price target lowered to $22 from $26 at Morgan Stanley
September 26, 2023 3:48 pmJacob JohnsonStephens$33.00$27.07Benzinga When Will Stevanato's Free Cash Flow Turn Positive? This Analyst Has An Answer
January 6, 2023 10:34 amMorgan Stanley$22.00$19.85Benzinga Morgan Stanley Maintains Overweight on Stevanato Group, Lowers Price Target to $22
April 25, 2022 9:20 amWells Fargo$19.00$16.59Benzinga Wells Fargo Maintains Overweight on Stevanato Group, Lowers Price Target to $19

Latest News for STVN

Stevanato Group: Alina Validates The Container-To-Device Flywheel

Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform, validated by commercial adoption of its Alina injector. High-value solutions now drive 45% of revenue, growing 16% year-over-year, with recent capacity investments in Fishers and Latina expected to boost operating leverage and margin expansion. STVN is shifting its portfolio toward premium,…

Seeking Alpha • Aug 29, 2026
Stevanato Group Q2 Earnings Call Highlights

Stevanato Group (NYSE: STVN) reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary. Revenue for the quarter reached €302 million, up 8% both on a reported and constant-currency

Defense World • Aug 11, 2026
Stevanato Group Q2 Earnings Call Highlights

Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.

MarketBeat • Aug 9, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for STVN.

No House trades found for STVN.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top